ETIB Clinical Trials

今年，我们发表了我们的II期研究结果，表明孟鲁司特可以安全地阻止闭塞性细支气管炎综合征的进展，这是造血细胞移植后慢性移植物抗宿主病（cGVHD）的严重表现。在一项合作研究中，我们在一组cGVHD成年患者中发现了高频率的肌肉骨骼症状。多变量logistic回归模型显示，在本研究中，一组联合因素与肌肉骨骼症状适度相关。此外，我们发现IFN基因标记的抑制可以在难治性系统性红斑狼疮（SLE）淋巴细胞消耗性自体造血细胞移植（AHSCT）后实现持久的临床和血清学缓解。

This year we published our phase II results, that suggest montelukast may safely halt the progression of bronchiolitis obliterans syndrome which is a severe manifestation of chronic graft-versus-host disease (cGVHD) following hematopoietic cell transplantation. In a collaborative study, we found a high frequency of musculoskeletal symptoms in a cohort of adult patients with cGVHD. The multivariable logistic regression models showed that a joint set of factors were moderately well associated with musculoskeletal symptoms in this study. In addition, we found durable clinical and serologic remissions with suppression in the IFN gene signature can be achieved in refractory systemic lupus erythematosus (SLE) following lymphodepleting autologous haematopoietic cell transplantation (AHSCT).